Spotlight Innovation’s development pipeline includes product candidates in areas of unmet medical need:

OUTSIDE INVESTMENT

CANCER

Spotlight Innovation subsidiary Celtic Biotech Iowa is developing novel therapeutic products for the treatment of cancer. Derived from specialized receptor binding proteins found in snake venom, these product candidates have the potential to reduce treatment costs, increase survival, and improve quality-of-life for cancer patients.

PRESS RELEASES

MARCH 10, 2017
Spotlight Innovation Commences Part 2 of Phase I Cancer Trial

NOVEMBER 10, 2016
Spotlight Innovation Subsidiary Celtic Biotech Iowa Receives Approval to Commence Phase I Part 2 Clinical Trial of Crotoxin

NOVEMBER 4, 2016
Spotlight Innovation Expands Its Patent Estate of Snake Venom-Derived Therapeutics

Back to top


CHRONIC PAIN

Spotlight Innovation subsidiary Caretta Therapeutics is developing and commercializing products—derived from cobra and rattlesnake venom—that have potential analgesic properties. Caretta Therapeutics has entered into a licensing agreement with Dr. Paul Reid for rights to develop and commercialize products derived from snake venom that may provide analgesic relief from moderate to severe chronic pain. Under the terms of the agreement, Dr. Reid has agreed to grant an exclusive, worldwide license to Caretta Therapeutics to develop, manufacture and sell the products. The products are intended to be available as over-the-counter formulations.

PRESS RELEASE

JUNE 14, 2017
Spotlight Innovation Subsidiary Caretta Therapeutics Signs Second Venodol API Production Agreement

MAY 31, 2017
Spotlight Innovation Subsidiary Caretta Therapeutics Begins the Manufacturing Process for Venodol, a New Over-the-Counter Product to Treat Chronic Pain

JANUARY 18, 2017
Spotlight Innovation Subsidiary Caretta Therapeutics Announces Venodol, a New Over-the-counter Product to Treat Chronic Pain

OCTOBER 6, 2016
Spotlight Innovation’s Newly Established Subsidiary Caretta Therapeutics Enters into Exclusive Licensing Agreement to Develop and Commercialize Analgesic Products

Back to top


ZIKA VIRUS INFECTION

Click the image above to watch Prof. Tang and his team discuss their small molecule screening program

Click the image above to watch Prof. Tang and his team discuss their small molecule screening program

Spotlight Innovation has obtained from the Florida State University Research Foundation exclusive, worldwide rights to develop and commercialize certain compounds for the treatment of viral infections, including Zika virus (ZIKV) infection. Included among the licensed compounds are those identified in a study co-authored by Florida State University Professor Hengli Tang that was published in Nature Medicine on August 29, 2016. The study reported two classes of compounds: one that protects Zika virus-infected neural cells from programmed cell death (“apoptosis”) and another that directly inhibits Zika virus replication. According to the study, when used in combination, compounds from the two classes enhanced the neuroprotective effect. In March 2016, Prof. Tang co-authored a study published in Cell Stem Cell that demonstrated for the first time the ability of ZIKV to target human embryonic cortical neural progenitor cells. Prof. Tang and his research team collaborate with Spotlight Innovation as part of an existing sponsored research agreement (SRA), and he is a member of the Company’s Scientific Advisory Board.

PRESS RELEASES

FEBRUARY 15, 2017
Spotlight Innovation Licenses Additional Anti-Zika Virus Compounds

DECEMBER 13, 2016
Spotlight Innovation Obtains Exclusive, Worldwide License from Florida State University Research Foundation to Commercialize Therapeutics for Zika Virus Infection

AUGUST 26, 2016
Spotlight Innovation Enters into Sponsored Research Agreement with Florida State University to Support Prof. Hengli Tang in the Development of Treatments for Zika Virus Infection

AUGUST 30, 2016
Spotlight Innovation Research Collaborator Prof. Hengli Tang Publishes Landmark Study in Nature Medicine

 

Back to top


SPINAL MUSCULAR ATROPHY

Spotlight Innovation has obtained an exclusive, worldwide license from Indiana University Research and Technology Corp. to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is a leading genetic cause of death in infants and toddlers. Spinal Muscular Atrophy affects between 1 in 6,000 and 1 in 10,000 newborns. Approximately 1 in 40 to 1 in 50 adults have only a single intact spinal motor neuron 1 (SMN1) gene, which encodes a protein (SMN) required for proper neuromuscular function. An infant who inherits no intact SMN1 gene from either parent may develop SMA and lose the ability to sit, stand, walk, swallow, and/or breathe. In about 60% of cases, patients with SMA die by age two.

PRESS RELEASES

JUNE 22, 2017
Spotlight Innovation to Present Poster at the Cure SMA 2017 Annual SMA Conference

FEBRUARY 8, 2017
Spotlight Innovation Engages Top-Tier Contract Research Organization to Conduct Preclinical Studies of STL-182

OCTOBER 19, 2016
Spotlight Innovation Launches Development of STL-182 to Treat Spinal Muscular Atrophy

Back to top


OUTSIDE INVESTMENT

REFRACTORY GLAUCOMA

Spotlight Innovation Inc. has made a strategic investment in Solx, Inc., a Massachusetts-based, privately-held medical device company. Solx’s lead product is the SOLX Gold Shunt™, a first-in-class, implantable drainage device designed to reduce elevated intraocular pressure (IOP) associated with refractory glaucoma without creating a bleb. The device provides a pathway for the flow of aqueous humor from the anterior chamber to the suprachoroidal space, utilizing a natural pressure differential within the eye. Approved for use in Canada and Europe, the SOLX Gold Shunt has been tested in a multi-center clinical trial, is investigational and is awaiting FDA approval in the U.S.

PRESS RELEASE

NOVEMBER 30, 2016
Spotlight Innovation Makes Strategic Investment in Solx, Inc.

Back to top